Valuation: Savara Inc.

Market Cap 1.23B 1.1B 1.01B 918M 1.73B 115B 1.79B 12.13B 4.84B 61.57B 4.61B 4.51B 194B P/E 2026 *
-8x
P/E 2027 * -12.4x
Enterprise Value 761M 683M 624M 570M 1.07B 71.57B 1.11B 7.52B 3B 38.19B 2.86B 2.8B 121B EV / Sales 2026 *
424x
EV / Sales 2027 * 11.3x
Free-Float
97.45%
Yield 2026 *
-
Yield 2027 * -
1 day+10.27%
1 week+0.21%
Current month+0.21%
1 month+3.87%
3 months-16.58%
6 months-8.35%
Current year-19.90%
1 week 4.32
Extreme 4.325
4.91
1 month 4.13
Extreme 4.13
5.14
Current year 4.13
Extreme 4.13
6.49
1 year 3.94
Extreme 3.945
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 59 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 73 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
24/9/26 Tax

Executive/Senior Manager

-29,323 0.0143%
15/7/26 Free

Chief Financial Officer

105,000 0.0512%
18/3/26 Exercice

Chief Financial Officer

850,254 0.4179%
Change 5-day change 1-year change 3-year change Capi.($)
+10.27%+0.21%+21.36%+31.97% 1.23B
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +1.31%+2.95%+52.68%+133.22% 40.7B
Weighted average by Cap. +0.24%+3.39%+53.02%+142.62%

Financials

2026 *2027 *
Net sales 1.8M 1.61M 1.47M 1.34M 2.53M 169M 2.61M 17.74M 7.07M 90.04M 6.74M 6.59M 284M 79.65M 71.44M 65.29M 59.6M 112M 7.49B 116M 787M 314M 3.99B 299M 293M 12.61B
Net income -151M -135M -124M -113M -213M -14.18B -219M -1.49B -594M -7.57B -566M -554M -23.89B -94.11M -84.41M -77.14M -70.42M -133M -8.85B -137M -930M -371M -4.72B -353M -346M -14.9B
Net Debt -466M -418M -382M -349M -657M -43.82B -678M -4.61B -1.84B -23.38B -1.75B -1.71B -73.81B -329M -295M -269M -246M -463M -30.88B -478M -3.25B -1.29B -16.48B -1.23B -1.21B -52.02B
Projected Income Statement - Annual - Savara Inc.
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
06/11/26 USD 4.830 +10.27% 2,226,928
05/11/26 USD 4.380 -6.01% 2,900,074
04/11/26 USD 4.660 -1.89% 3,560,043
03/11/26 USD 4.750 +0.42% 2,110,956
02/11/26 USD 4.730 -1.87% 1,777,700
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Savara Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.830USD
Average target price
11.06USD
Spread / Average Target
+128.89%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Savara Inc.
  1. Stock Market
  2. Stocks
  3. SVRA Stock